Deborah A. Nicoll‐Griffith
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Inflammatory mediators and NSAID effects, Eicosanoids and Hypertension Pharmacology, Analytical Chemistry and Chromatography, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → Drug−Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development(2003)704 cited
- → The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K(2008)470 cited
- → Managing the challenge of chemically reactive metabolites in drug development(2011)450 cited
- Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.(1998)
- → Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets.(1994)258 cited
- → MS E with mass defect filtering for in vitro and in vivo metabolite identification(2007)254 cited
- In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse.(1997)